Panacea Biotec Limited has informed the Exchange regarding a press release dated Jun 03, 2025, titled "Press Release - Inclusion of EmulsiPan adjuvant in the CEPI Adjuvant Library and its foray into commercialisation of its indigenously developed adjuvants".
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts less than Nifty Microcap 250 and 4.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Panacea Biotec announced that its in-house developed adjuvant 'EmulsiPan' has been included in the CEPI (Coalition for Epidemic Preparedness Innovations) Adjuvant Library, an international platform that supports vaccine and biotherapeutic research. EmulsiPan is an oil-in-water emulsion adjuvant originally developed in 2009 and used in the company's H1N1 vaccine PandyFlu. The product has been used in preclinical studies including COVID-related vaccine work with Caltech and India's THSTI. The company is now commercialising the adjuvant on an open-access, royalty-free basis for vaccine developers globally, with no licensing fees. The global adjuvant market is estimated to cross $4.8 billion by 2028, providing context for the commercial opportunity. The company has over 1,500 global patents and a track record in polio and combination vaccines.
This is a scientific validation and a soft entry into a niche but growing global market rather than a confirmed order or revenue trigger. Positively, it opens a new, asset-light revenue stream through adjuvant sales, but near-term impact on the stock is likely to be limited as commercial scale-up and demand will take time to materialise.